ArticleLupus science & medicine2025
Prevalence and incidence of systemic lupus erythematosus in Thailand based on national health data.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HLA - C*03:02:02 and DPA1*01:03:01 protect against discoid rash in Thai Systemic Lupus Erythematosus patients.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSLE is an autoimmune disease that varies across ethnic populations and the regions that cause economic burdens, but nationwide epidemiological data for Thailand are lacking.
objectiveTo estimate the incidence and prevalence of SLE in Thailand between 2017 and 2020.
methodsA retrospective cohort study used the Information and Communication Technology Center, Ministry of Public Health, covering all major healthcare insurance systems (nearly 90% of hospitals, about 80% of the Thai population). Adults (≥18 years) with a primary diagnosis of SLE (International Classification of Diseases 10th Revision code M32) were included. Point and period prevalence (per 100 000 population) and annual incidence rates (per 100 000 person-years) were calculated overall and stratified by year, age, sex and region, with 95% CIs.
resultsIn 2017, 55 956 prevalent cases were identified among 65 204 797 of the total Thai population, yielding a point prevalence of 85.8/100 000 (95 % CI 85.1 to 86.5). Prevalence was highest in women (152.9 vs 15.9/100 000; female-to-male ratio 9.6:1), in the 40-49 year age group (128.3/100 000) and in the southern region (178.5/100 000). From 2018 to 2020, incident SLE cases numbered 15 403, 16 243 and 15 925, corresponding to annual incidence rates of 23.6, 24.8 and 24.3/100 000 person-years, and the cumulative incidence for the 3 years was 72.7/100 000 person-years (95 % CI 72.0 to 73.4). Incidence peaked at ages 40-49 in 2019 (33.7/100 000) and was consistently highest in the south (60.0, 53.9 and 57.3/100 000 person-years in 2018-2020).
conclusionsSLE is relatively common in Thailand, particularly among women of reproductive age and residents of the southern region. These nationwide data support SLE service planning in Thailand and may guide resource allocation in other Southeast Asian health systems expanding universal coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.